We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Streamlining the Analysis of Free Drug Content in ADCs

3D rendering of antibody-drug conjugates (ADCs) in a blue molecular environment, showcasing complex antibody structures.
Credit: iStock

Antibody–drug conjugates (ADCs) are complex therapeutic biomolecules engineered to specifically target and eliminate cancerous cells while preserving healthy cells.


However, the presence of free drug and related species in the final ADC product could lead to compromised product efficacy and increased toxicity.


This application note presents a method that integrates protein elimination and free drug identification into one analysis using a two-dimensional liquid chromatography/quadrupole time-of-flight mass spectrometry (2D-LC/Q-TOF) approach.


Download this application note to discover:

  • An innovative method for the identification of free drug content in ADCs
  • A sensitive analysis of free drug content without manual protein precipitation
  • An integrated approach to save time and achieve superior chromatographic separation
Brought to you by

Download the Application Note for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.